Following entry into toxicological studies and clinical Phases I to III, Cevec is expected to receive undisclosed milestone payments after market approval.
Cevec claimed that the transient CAP-T protein production technology is based on CAP cells, a human immortalised cell line for stable protein production derived from amniocytes and developed by the company.
The non-tumor origin cell lines exhibit high protein expression levels even for difficult to express proteins. They have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.
The platform allows efficient protein production from research, development and scale up to large scale manufacturing in high-volume bioreactors.
Pevion Biotech claimed that the target protein is part of a vaccine that the company intends to develop based on its proprietary and market-validated virosome technology platform.
Rainer Lichtenberger, CEO of Cevec, said: “The signing of this agreement is a milestone for Cevec since it represents our first exclusively granted license for a clinically relevant protein produced in our CAP cells.
“We’re proud that Pevion Biotech has chosen our CAP technology expression platform to produce a technically demanding protein.”